DurgicalDurgical
EN
Open the app

Atracurium !

Non-depolarising muscle relaxant that breaks down by itself in the blood (Hofmann elimination): useful in liver or kidney failure. It releases histamine.

Updated 2026-11-01

  • Class: Neuromuscular blockers
  • Receptor: Muscle nicotinic acetylcholine receptor (motor end plate)
  • ATC code: M03AC04
  • WHO Model List of Essential Medicines

Also called: Atracurium besilate

There is no structure with atracurium. The figure shows d-tubocurarine, another benzylisoquinoline, at the acetylcholine site of the Torpedo ray muscle-type nicotinic receptor.

Target in 3D: Muscle nicotinic acetylcholine receptor (motor end plate). PDB structure 7SMS (RCSB PDB, public domain). View the structure at RCSB PDB

Mechanism of action

Atracurium, a benzylisoquinoline, competes with acetylcholine at the nicotinic receptor of the motor end plate without activating it. Its distinctive feature is elimination: it breaks down in plasma by ester hydrolysis and by Hofmann elimination, a chemical process that does not depend on enzymes, the liver or the kidney and occurs at physiological pH. One of its products is laudanosine.

  1. Competes with acetylcholine at the nicotinic receptor
  2. Flaccid paralysis of intermediate duration
  3. Breaks down in blood (Hofmann and esters) without liver or kidney
  4. Releases histamine with high doses or rapid injection

Pharmacokinetics

Metabolism
Hofmann elimination (chemical, non-enzymatic) and hydrolysis by non-specific esterases; produces laudanosine.
Elimination
The metabolites leave in urine and bile; duration barely changes with renal or hepatic failure.

Indications

  • Tracheal intubation and muscle relaxation in surgery
  • Patients with liver or kidney failure who need neuromuscular block

Adverse effects

Common

  • Skin flushing
  • Transient hypotension
  • Tachycardia

Contraindications

  • Hypersensitivity to atracurium
  • Multiple-dose vials with benzyl alcohol: hypersensitivity to benzyl alcohol; avoided in newborns

Key interactions

Halogenated agents, aminoglycosides, magnesium, lithium
Enhance the block.
Alkaline solutions (barbiturates)
Incompatible; atracurium is inactivated or precipitates.

What is monitored

  • Train-of-four
  • Blood pressure and signs of histamine release (flushing, bronchospasm)
  • Ventilation and saturation

Administration and safety

  • Keep refrigerated and protected from light; at room temperature it loses potency.
  • In patients with heart disease or a history suggesting a higher risk of histamine release (asthma, anaphylactoid reactions), it is injected more slowly.
  • Do not mix with alkaline solutions in the same syringe or line.
  • Paralysing agent: store apart with warnings.

Nursing care

  • Watch blood pressure, flushing and wheeze after injection.
  • Train-of-four and sedation assessment.
  • With long ICU infusions: watch for seizures.
  • After reversal: strength, breathing and saturation.

Pregnancy and breastfeeding

Small amounts cross the placenta; it has been used for caesarean sections without attributable effects in the newborns, who are watched for respiratory depression.

Test yourself

Think of the answer, then tap the question to see it.

What is Hofmann elimination?

A spontaneous, non-enzymatic chemical breakdown that occurs in plasma at physiological pH; it eliminates atracurium and cisatracurium.

Why is atracurium useful in liver or kidney failure?

Its elimination does not depend on those organs: it breaks down in the blood by Hofmann elimination and esterases.

Which atracurium metabolite can cause cerebral excitation?

Laudanosine, which causes seizures at high doses in animals.

Add to my cards (3)

← Back to the class: Neuromuscular blockers

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: DailyMed - ATRACURIUM BESYLATE injection, solution (DailyMed (U.S. National Library of Medicine), 2026); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 13 (McGraw Hill, 2023); eEML - Electronic Essential Medicines List (World Health Organization, 2025); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.